Vaxart Urges Shareholders to Back Its Board Nominees Amid Proxy Fight
Event summary
- Vaxart published a presentation urging shareholders to vote for all six of its director nominees on the WHITE proxy card ahead of its July 16, 2026 Annual Meeting.
- The company highlights strategic actions taken by its board, including securing BARDA funding and raising $40 million in 2025 to extend its runway.
- Vaxart criticizes dissident nominees for lacking relevant clinical-stage biotech expertise and misrepresenting their qualifications.
- The company has made multiple settlement offers to the dissident shareholder group, which have been rejected by Daniel Houle.
The big picture
Vaxart's proxy fight underscores the tension between its current board, which emphasizes strategic execution and securing funding, and dissident shareholders pushing for change. The contest comes at a critical juncture as the company advances multiple vaccine programs and navigates regulatory and funding challenges in the biotech sector.
What we're watching
- Governance Dynamics
- Whether Vaxart's current board can maintain shareholder support amid the proxy contest and secure votes for all six nominees.
- Funding Strategy
- The pace at which Vaxart can advance its pipeline with existing capital, particularly as it awaits key clinical readouts.
- Clinical Milestones
- How the topline 12-month safety and immunogenicity data from the Phase 2b COVID-19 trial will impact investor confidence.
Related topics